EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Measuring treatment response in psoriatic arthritis: comparison between PSoriatic Arthritis Response Criteria and Disease Activity Score

Khadijah Patel iD, Moshiur Rahman Khasru iD, Nisha Nair iD, Maarten De Wit, Arnon Katz iD, Charlotte Thompson iD, Meghna Jani iD, Hector Chinoy iD, Anne Barton iD, Philippa Curry iD, James Bluett iD, OUTPASS Collaborators

Rheumatology Advances in Practice · 21.09.2026 · 10 (4)

DOI: 10.1093/rap/rkag120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology Advances in Practice, online erschienen am 08.10.2026. Verfasst von Khadijah Patel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Versus Arthritis, National Institute for Health Research Manchester Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Despite current UK guidelines recommending the use of the PSoriatic Arthritis Response Criteria (PsARC) to assess response to advanced targeted therapies in PsA patients, some clinicians use the 28-joint Disease Activity Score (DAS28), primarily developed for RA. Concordance of the two scores in PsA patients commencing advanced therapies has not previously been explored and is investigated here.

Methods

Utilising data from the Outcomes of Treatment in Psoriatic Arthritis Study Syndicate (OUTPASS – RDN-CPMS 13910) cohort, a UK multicentre, observational study, components of PsARC and DAS28 scores were calculated at baseline (pretreatment), 3 months and 6 months following treatment, where available. DAS28-based good/moderate responses were combined and compared with PsARC responder status and agreement tested using the prevalence-adjusted bias-adjusted kappa test.

Results

Of 413 patients, 78% were classified as responders by PsARC at 3 months and 73% at 6 months and 80% by DAS28 at both 3 and 6 months. Of 218 visits, where data were recorded for patients with both PsARC and DAS28 at 3 or 6 months, 17.9% were overall discordant. Prevalence-adjusted bias-adjusted kappa values revealed ‘substantial agreement’ (64.22%) between the two scores. Further analysis between the overall concordant/discordant populations showed significant differences with PsARC patient global assessments (PtGAs), (P = 0.02).

Conclusion

PsARC and DAS28-based response criteria show ‘substantial agreement’, supporting the use of either score in patients commencing advanced therapies. PsARC PtGA was the sole significantly different (P < 0.05) subcomponent between the discordant and concordant groups, highlighting an importance in considering patient perspectives and psychosocial factors affecting response to treatment.

Schlagwörter

Stichwörter der Autor:innen

biological therapiesobservational studiesoutcome measurespain assessmentpsoriatic arthritis

Autor:innen und Institutionen

  • Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK.
  • GRAPPA Patient Research Partner, The Netherlands.
  • GRAPPA Patient Research Partner, Israel.
  • Department of Rheumatology, University Hospitals Sussex NHS Foundation Trust, Sussex, UK.
  • Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK.

ORCID-Profile: Khadijah Patel, Moshiur Rahman Khasru, Nisha Nair, Arnon Katz, Charlotte Thompson, Meghna Jani, Hector Chinoy, Anne Barton, Philippa Curry, James Bluett

Förderung

  • Versus Arthritis
  • National Institute for Health Research Manchester Biomedical Research Centre

Zitieren

APA

Patel, K., Khasru, M. R., Nair, N., De Wit, M., Katz, A., Thompson, C., Jani, M., Chinoy, H., Barton, A., Curry, P., Bluett, J., & OUTPASS Collaborators (2026). Measuring treatment response in psoriatic arthritis: comparison between PSoriatic Arthritis Response Criteria and Disease Activity Score. Rheumatology Advances in Practice, 10(4). https://doi.org/10.1093/rap/rkag120

Vancouver

Patel K, Khasru MR, Nair N, De Wit M, Katz A, Thompson C, et al. Measuring treatment response in psoriatic arthritis: comparison between PSoriatic Arthritis Response Criteria and Disease Activity Score. Rheumatology Advances in Practice. 2026;10(4). doi:10.1093/rap/rkag120

BibTeX
@article{Patel2026,
  author = {Patel, Khadijah and Khasru, Moshiur Rahman and Nair, Nisha and De Wit, Maarten and Katz, Arnon and Thompson, Charlotte and Jani, Meghna and Chinoy, Hector and Barton, Anne and Curry, Philippa and Bluett, James and OUTPASS Collaborators, OUTPASS Collaborators},
  title = {Measuring treatment response in psoriatic arthritis: comparison between PSoriatic Arthritis Response Criteria and Disease Activity Score},
  journal = {Rheumatology Advances in Practice},
  year = {2026},
  volume = {10},
  number = {4},
  doi = {10.1093/rap/rkag120}
}
Kostenlos starten →